<code id='B3DCFA4324'></code><style id='B3DCFA4324'></style>
    • <acronym id='B3DCFA4324'></acronym>
      <center id='B3DCFA4324'><center id='B3DCFA4324'><tfoot id='B3DCFA4324'></tfoot></center><abbr id='B3DCFA4324'><dir id='B3DCFA4324'><tfoot id='B3DCFA4324'></tfoot><noframes id='B3DCFA4324'>

    • <optgroup id='B3DCFA4324'><strike id='B3DCFA4324'><sup id='B3DCFA4324'></sup></strike><code id='B3DCFA4324'></code></optgroup>
        1. <b id='B3DCFA4324'><label id='B3DCFA4324'><select id='B3DCFA4324'><dt id='B3DCFA4324'><span id='B3DCFA4324'></span></dt></select></label></b><u id='B3DCFA4324'></u>
          <i id='B3DCFA4324'><strike id='B3DCFA4324'><tt id='B3DCFA4324'><pre id='B3DCFA4324'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:88431
          the shape of a medical note connected by dots and lines — health tech coverage from STAT
          Adobe

          In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

          But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

          advertisement

          This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Biotech reporter’s notebook: A sunnier mood at JPM 2024
          Biotech reporter’s notebook: A sunnier mood at JPM 2024

          AlexHogan/STATSANFRANCISCO—Itseemedliketherewasapointduringlastyear’sJ.P.MorganHealthcareConferencew

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S